B. Braun recalls two lots of Lactated Ringer’s Injection

B. Braun Medical has launched a voluntary nationwide recall of two lots of Lactated Ringer’s Injection, E7500, 1L, after the company found particulate matter in solution, according to an FDA-posted company announcement dated April 28, 2026. The recall is being carried out to the hospital and healthcare facility level, and it covers product distributed across the U.S. to distributors, hospitals, and healthcare facilities. (fda.gov)

The recalled product is a familiar one. B. Braun markets Lactated Ringer’s Injection in several container formats, including the 1,000 mL E3 IV container sold under product code E7500. FDA labeling shows that E7500 corresponds to NDC 0264-7750-07, the same identifier listed in the recall notice. Lactated Ringer’s remains a standard isotonic balanced crystalloid used for hydration and electrolyte replacement, so any quality-related recall involving a 1 L presentation is likely to draw attention from clinicians and supply managers alike. (bbraunusa.com)

The two affected lots are J4P756 and J4S843. According to the recall notice, lot J4P756 was distributed from November 15, 2024, through March 6, 2025, and lot J4S843 from January 13, 2025, through May 15, 2025. Both lots carry an expiration date of May 31, 2027. B. Braun said complaint investigations identified the particles as cellulose and stearates, with extremely low levels of inorganic material such as copper. The company also said it had not received reports of adverse events tied to the recall as of April 28. (fda.gov)

The risk assessment in the FDA-posted notice is more serious than the absence of reported injuries might suggest. B. Braun said particulate-contaminated IV fluid has a reasonable probability of causing pulmonary emboli, occlusion of other blood vessels, phlebitis, systemic immune activation, organ dysfunction, and hemolysis. If particles are seen before administration, the company noted, the immediate consequence may simply be a delay while replacement product is obtained, but the hazard rises sharply if contaminated fluid reaches the bloodstream. (fda.gov)

Industry reaction appears limited so far, with the main public documentation coming from the FDA repost of B. Braun’s announcement and downstream alerts that largely restate the same notice. I did not find substantial independent expert commentary specific to this recall. That said, the event fits a broader pattern in sterile injectable quality oversight, where visible or subvisible particulate matter can trigger rapid distribution-level action because the route of administration leaves little margin for error. As context, FDA’s drug recalls index lists the B. Braun Lactated Ringer’s recall under particulate matter in solution, underscoring that the issue has entered the agency’s formal recall tracking system. (fda.gov)

Why it matters: For veterinary professionals, this is less about a labeled veterinary product than about crossover supply risk. Many emergency and specialty hospitals, university services, and large practices purchase human-labeled IV fluids through medical distributors, and Lactated Ringer’s is deeply embedded in everyday fluid therapy workflows. Teams should check shelves and crash-cart stock for E7500, verify lot numbers J4P756 and J4S843, and make sure pharmacy, nursing, and purchasing staff know the recall applies specifically to the 1 L E3 container format. Because B. Braun is arranging returns and notifying customers by mail, practices that buy through intermediaries may need to confirm whether their distributor has already quarantined affected inventory. (fda.gov)

This also lands in a market where fluid availability can matter operationally. Even a narrow recall can create friction if it affects a high-turnover SKU, especially for hospitals trying to standardize balanced crystalloids across services. If veterinary hospitals need to substitute, clinicians and technicians may need to review container compatibility, storage, and workflow differences among available alternatives, even when the underlying fluid choice remains clinically routine. That’s an inference based on the product’s common use and the recall’s hospital-level scope, rather than a statement made directly by the company. (bbraunusa.com)

What to watch: The next markers are whether FDA assigns or updates a recall classification, whether distributors report any downstream availability issues, and whether B. Braun expands, narrows, or closes the action as return processing continues. For now, the key timeline anchor is April 28, 2026, the date the company announcement and FDA posting went live. (fda.gov)